Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study-Reference-Cited by-同舟云学术

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study

Published:2022-06-25 Issue:4 Volume:17 Page:467-474
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Maruzzo Marco^ORCID,Pierantoni Francesco,Bortolami Alberto,Palleschi Dario,Zivi Andrea,Nicodemo Maurizio,Sartori Donata,De Vivo Rocco,Zustovich Fable,Bimbatti Davide,Pastorelli Davide,Vultaggio Giuseppe Dione,Soraru’ Mariella,Ballestrin Melissa,Modonesi Caterina,Randisi Paola,Barile Carmen,Perri Gino,Basso Umberto,Zagonel Vittorina

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-022-00892-z.pdf

Reference38 articles.

1. Capitanio U, Montorsi F, Larcher A. Surgical safety of cytoreductive nephrectomy following systemic therapy: what should we look for? Eur Urol. 2019;76(4):441–2. https://doi.org/10.1016/j.eururo.2019.07.007.

2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24. https://doi.org/10.1056/NEJMoa065044.

3. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31. https://doi.org/10.1056/NEJMoa1303989.

4. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet. 2011;378(9807):1931–9. https://doi.org/10.1016/S0140-6736(11)61613-9.

5. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34. https://doi.org/10.1056/NEJMoa060655.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases;Global and Regional Health Technology Assessment;2024-07-03

2. Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England;Drugs - Real World Outcomes;2024-01-24

3. Cabozantinib in the Routine Management of Renal Cell Carcinoma: A Systematic Literature Review of Real-World Evidence;Clinical Genitourinary Cancer;2023-11

4. Real-World Evidence—Current Developments and Perspectives;International Journal of Environmental Research and Public Health;2022-08-16